This talk maps the evolution of ATMP immunotherapies for autoimmune diseases from TNF-α– targeted biologics to emerging immune cell and pathway targets, and highlights ACROBiosystems’ integrated solutions enabling development from discovery to clinic.
Hui Yu, Field Application Development Director, ACRO Biosystems